Our data showed that both IL-6-neutralizing and CSF-1-neutralizing antibodies reduced CD206+ cell population in CD11b+ mouse BM macrophages treated with glioma-CM-pretreated ECs, but did not affect CD11b+CD86+CD206− population (Fig. 4a, b), suggesting a crucial role of IL-6 and CSF-1 in EC-induced alternative macrophage activation. The gene discussed is CD86; the disease is central nervous system cancer.